Egyptian International Pharmaceuticals (EIPICO) (PHAR)
Egyptian Exchange · Egypt · prices in EGP · close of 22 Oct 2026
Key indicators
| Last close | EGP 101.90 |
|---|---|
| 52-week range | 67.50 – 178.99 |
| Return, 1 month / 3 months | −11.8% / +11.4% |
| Return, 1 year / 3 years | +25.3% / +187.0% |
| Trend | Above 200-day, below 50-day |
| RSI (14) | 35 |
| Volatility (1 year) | 46.2% |
| Worst drawdown (1 year) | -36.6% |
| Average daily value traded | 245.00M EGP |
| Dividend yield | 1.5% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Egyptian International Pharmaceuticals, known as EIPICO, is a pharmaceutical manufacturer based in Egypt. The company develops and produces generic prescription medicines, including antibiotics and treatments for a range of common conditions, along with pharmaceutical raw materials and packaging materials. It serves patients and healthcare providers through pharmacies and hospitals in its home market, and it also supplies its products to customers in other countries across the region and beyond.
The shares are listed on the Egyptian Exchange in Egypt under the code PHAR, and the price on this page is in Egyptian pounds (EGP). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Egyptian International Pharmaceuticals (EIPICO) (PHAR) trades on the Egyptian Exchange in Egypt. It last closed at EGP 101.90 on 22 October 2026.
Its price-based Market X-Ray is 60 out of 100 (a fair price profile), ranking 78 of 276 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 25.3% and over the last three months it rose 11.4%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Egyptian Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 57 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 7.9% | ||
| From 52-week high | -36.4% | ||
| Momentum | 64 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 11.4% | ||
| 6-month return | 20.3% | ||
| 12-month return, skipping the last month | 42.1% | ||
| Stability (higher is calmer) | 42 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 46.2% | ||
| Worst drawdown, 1 year (smaller is calmer) | -36.6% | ||
| Liquidity | 98 · Strong | Trades actively. | |
| Average daily value traded | 245.00M EGP | ||
| Zero-volume days | 0.0% | ||
| Income | 48 · Weak | Dividend is small or irregular. | |
| Dividend yield | 1.5% | ||
| Years with dividends | 5 |
Strengths
- Liquidity: Trades actively.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Income: Dividend is small or irregular.
Returns
| 1 week | −5.3% |
|---|---|
| 1 month | −11.8% |
| 3 months | +11.4% |
| 6 months | +20.3% |
| 1 year | +25.3% |
| 3 years | +187.0% |
| 5 years | +262.9% |
Signals
| 50-day / 200-day average | 120.16 / 94.43 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | Yes |
| Average daily range (ATR) | 4.90 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 28 Apr 2026 | EGP 1.5000 |
| 22 Apr 2025 | EGP 1.5000 |
| 28 Apr 2024 | EGP 1.0000 |
| 19 Apr 2023 | EGP 1.0000 |
| 20 Apr 2022 | EGP 1.5000 |
| 26 Apr 2021 | EGP 2.9500 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Egyptian Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.